Home
Search
Search Results
Previously Searched
3113 results found
Expand All
Apply All
3113 results found

BIO Comments to FTC on Revised HSR Form
Letters, Testimony & Comments  •  September 27, 2023
Comments on Revised HSR Premerger Notification and Report Form 16 CFR Parts 801-803—Hart-Scott-Rodino Coverage, Exemption, and Transmittal Rules, Project No. P239300
Read More
FTC HSR Comments

ICER still ignores patient concerns
Good Day BIO Newsletter  •  September 27, 2023
We take a deep dive into ICER’s updated treatment assessment—plus, how biotech is making crops more resilient in the face of an increasingly harsher climate. (609 words, 3 minutes, 2 seconds)
Read More

Inflation Reduction Act One Year Later— Where Are We Now? What Other Challenges are on the Horizon?
Webinars  •  September 27, 2023
​It's been one year since the passage of the IRA. The Centers for Medicare & Medicaid Services has moved forward implementing the law's various provisions, including the new Medicare negotiation program and the redesign of the Medicare Part D benefit. Learn the latest developments from our panel of experts, including how the IRA is impacting biopharmaceutical companies today. Panelists delve into other important issues beyond the IRA, including new developments in Medicaid, 340B, and the emergence of Prescription Drug Affordability Boards in a number of states.  
Read More
photo of pills in capped bottles

How PBMs profit
Good Day BIO Newsletter  •  September 26, 2023
Several new studies highlight the growing problem of PBMs—plus, Bio.News has an exclusive look at the growing “biotech sisterhood” and how women CEOs are helping women colleagues and patients. (550 words, 2 minutes, 45 seconds)
Read More

Infants have another shot at fighting RSV
Good Day BIO Newsletter  •  September 25, 2023
Starting a new week with another option to protect infants from RSV and BIO’s MOU with Vietnam’s state pharma company. (513 words, 2 minutes, 33 seconds)
Read More

Alternative funding programs draw patient scrutiny
Good Day BIO Newsletter  •  September 22, 2023
Ending a busy week with a recap of John Crowley’s testimony on Capitol Hill yesterday and a look at the problems with alternative funding programs—plus, what companies and investors are saying about the BIO Investor Forum. (508 words, 2 minutes, 32 seconds)
Read More

BIO Office Hours: SBIR/Federal Grant Writing
September 21, 2023
January 2024 holds critical submission deadlines, and now is the time to start planning and drafting. Do you know the funding opportunities that align with your R&D? Not sure if your application satisfies all requirements? Back by popular demand, grant writing experts from PSC Biotech are hosting twenty-minute virtual appointments to answer questions and provide resources to inform your overall grant conceptualization. What to expect in the overview & 20-minute Zoom session: Help identifying opportunities that match your company's R&D Strategies for SBIR/STTR grant submissions Suggested timelines and project management Schedule Office Hour
Read More

BIO tells Congress price controls hurt R&D
Good Day BIO Newsletter  •  September 21, 2023
Price controls are already hurting drug R&D, especially for rare disease, BIO’s Vice Chair John Crowley told Congress yesterday. Meanwhile, in New York, BIO’s SVP Phyllis Arthur spoke on a panel during the UN General Assembly about what we need to do to get ready for the next pandemic. (653 words, 3 minutes, 15 seconds)
Read More

Testimony of John F. Crowley, Executive Chairman of Amicus Therapeautics, to the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations  for the hearing “How the IRA’s Price Setting Scheme Means Fewer Cures for Patients”
Letters, Testimony & Comments  •  September 20, 2023
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
Read More

BIO Office Hours: SBIR/Federal Grant Writing
September 20, 2023
January 2024 holds critical submission deadlines, and now is the time to start planning and drafting. Do you know the funding opportunities that align with your R&D? Not sure if your application satisfies all requirements? Back by popular demand, grant writing experts from PSC Biotech are hosting twenty-minute virtual appointments to answer questions and provide resources to inform your overall grant conceptualization. What to expect in the overview & 20-minute Zoom session: Help identifying opportunities that match your company's R&D Strategies for SBIR/STTR grant submissions Suggested timelines and project management   Schedule Office Hour
Read More